Ocular Therapeutix reported strong progress in its third quarter of 2025 with key milestones reached in its clinical trials for AXPAXLI, positioning the company for a potential market shift in retinal therapies.

• Successfully reached target randomization of 555 subjects in the SOL-R trial for wet AMD, indicating strong investigator engagement and execution.
• Launched the HELIOS program aimed at gaining a superiority label for AXPAXLI in both diabetic retinopathy and non-proliferative diabetic retinopathy (NPDR), aiming to capture a broader patient population.
• Phase III trial SOL-1 anticipates releasing top-line data in Q1 2026, which could position AXPAXLI as a distinct first-line treatment in a commoditized market currently dominated by anti-VEGF therapies.